Visual Field Test Logo

Cost-effectiveness

āļāļēāļĢāļ§āļīāļˆāļąāļĒāđ€āļŠāļīāļ‡āļĨāļķāļāđāļĨāļ°āļ„āļđāđˆāļĄāļ·āļ­āļœāļđāđ‰āđ€āļŠāļĩāđˆāļĒāļ§āļŠāļēāļāđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļāļēāļĢāļĢāļąāļāļĐāļēāļŠāļļāļ‚āļ āļēāļžāļŠāļēāļĒāļ•āļēāļ‚āļ­āļ‡āļ„āļļāļ“

AI for Glaucoma Detection and Prognosis: Performance, Bias, and Clinical Integration in 2025

AI for Glaucoma Detection and Prognosis: Performance, Bias, and Clinical Integration in 2025

AI for Glaucoma Detection and Prognosis: Performance, Bias, and Clinical Integration in 2025 Glaucoma is a leading cause of irreversible blindness, affecting over 90 million people worldwide (pmc.ncbi.nlm.nih.gov). Worryingly, more than 70% of glaucoma cases remain undiagnosed (pmc.ncbi.nlm.nih.gov). Early detection is crucial because vision loss from glaucoma cannot be undone. In recent years, a...

The Economics of Glaucoma Care in 2025: Screening, Devices, and Drugs

The Economics of Glaucoma Care in 2025: Screening, Devices, and Drugs

Introduction Glaucoma affects tens of millions worldwide and is the second leading cause of irreversible blindness after cataract (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Most cases progress silently, and roughly 3% of adults over 40 have glaucoma – the majority undiagnosed (pmc.ncbi.nlm.nih.gov). Visual loss from glaucoma heavily degrades quality of life and raises lifetime costs; one s...

āļžāļĢāđ‰āļ­āļĄāļ—āļĩāđˆāļˆāļ°āļ•āļĢāļ§āļˆāļŠāļēāļĒāļ•āļēāļ‚āļ­āļ‡āļ„āļļāļ“āļŦāļĢāļ·āļ­āļĒāļąāļ‡?

āđ€āļĢāļīāđˆāļĄāļāļēāļĢāļ—āļ”āļŠāļ­āļšāļĨāļēāļ™āļŠāļēāļĒāļ•āļēāļŸāļĢāļĩāļ‚āļ­āļ‡āļ„āļļāļ“āđƒāļ™āđ€āļ§āļĨāļēāļ™āđ‰āļ­āļĒāļāļ§āđˆāļē 5 āļ™āļēāļ—āļĩ

āđ€āļĢāļīāđˆāļĄāļ—āļ”āļŠāļ­āļšāļ—āļąāļ™āļ—āļĩ

cost-effectiveness

A way to compare how much benefit a health care option gives for its cost, like treatments or screenings. It helps doctors and policymakers decide which services give the best value for improving eye health.